Gujarat Themis Biosyn zooms 14% on acquiring Sanofi's TB drug portfolio

The buying on the counter came after Gujarat Themis Biosyn signed an Asset Purchase Agreement with Sanofi to acquire a ...

Gujarat Themis Biosyn Acquires Sanofi Portfolio In ₹1,738 Crore Deal To Expand Global Reach

Mumbai: Gujarat Themis Biosyn is making a decisive global push, betting on a high-value pharmaceutical portfolio to scale ...

Gujarat Themis Biosyn to Buy Sanofi’s Global Anti-TB and Anti-Infective Brands

Gujarat Themis Biosyn Ltd has signed an asset purchase agreement to acquire Sanofi’s global portfolio of 13 anti-tuberculosis and anti-infective branded generics. The deal, subject to antitrust and ...
Medscape

THEMIS: A Role for Ticagrelor in Diabetic Patients With Prior PCI?

PARIS — For patients with type 2 diabetes and stable coronary artery disease, the benefits of adding ticagrelor (Brilinta/Brilique, AstraZeneca) to aspirin in terms of reduced ischemic events did not ...

Gujarat Themis Biosyn Unveils Investor Presentation on Sanofi Anti-TB Asset Purchase

An update from Gujarat Themis Biosyn Ltd ( (IN:GUJTHEM) ) is now available.
Yahoo Finance

Themis Secures $9M Seed Round to Accelerate Partnerships by Reducing Regulatory and Compliance Barriers

Themis is a purpose-built collaboration tech platform designed for banks, fintechs, and crypto NEW YORK, NY / ACCESSWIRE / April 19, 2022 / Themis, a collaborative governance, risk, and compliance ...
Business Insider

Check out the 9-page pitch deck Themis, which offers pay-as-you-go compliance for banks, fintechs, and crypto startups, used to raise $9 million in seed funding

Financial firms are spending billions on increasingly onerous compliance rules each year. Themis offers pay-as-you-go risk-management and compliance for banks, fintechs and crypto startups. See the ...